Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Privi Speciality Chemicals reported a strong Q1 FY26, with standalone revenue rising 29.6% year-on-year to Rs 574.7 crore and consolidated revenue up 21.7% to Rs 567.8 crore. Standalone EBITDA jumped 50.4% to Rs 144.7 crore while consolidated EBITDA grew 45.3% to Rs 141.1 crore, with EBITDA margins expanding about 350-400 basis points on both bases. Standalone PAT more than doubled (+113%) to Rs 68.7 crore and consolidated PAT rose 97% to Rs 61.9 crore; ROCE improved 500 bps and ROE 670 bps. Management highlighted that Phase 1 of its specialty aroma chemicals capacity expansion is partly complete and will contribute from Q2 FY26, with the full project slated for Q4 FY26. The company also announced a proposed amalgamation of subsidiaries Privi Fine Sciences and Privi Biotechnologies into PSCL to unlock synergies, and noted its EcoVadis Platinum rating placing it in the top 1% globally for ESG.
Sharply higher revenue, EBITDA and PAT growth with margin expansion signal strong operational momentum and should be viewed positively by shareholders. The capacity ramp-up from Q2 FY26 and the consolidation of subsidiaries could further support earnings, though net debt has risen and the new subsidiary Prigiv is still loss-making.